Emvena Therapeutics launches with seed funding from the Penn-BioNTech PxB Fund to build placenta-targeted mRNA medicines.

AbbVie licenses Nxera's oral EP4 agonist NXE0033744 for IBD in a $100M upfront global deal. Read the key terms and what this ...

A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...

Novo Nordisk Q3 2026 earnings show CagriSema outperforming tirzepatide in weight loss. Explore the full pipeline update, ...

Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up ...

Pfizer Q3 2026 earnings: second positive Elrexfio Phase III readout, atirmociclib tolerability data and mevrometostat delay.

AstraZeneca withdraws its EU application for Truqap in PTEN-deficient prostate cancer after a CHMP provisional opinion. Read ...

AN2 Therapeutics receives FDA IND clearance for epetraborole in polycythemia vera, completing approvals in Australia, India ...

Servier's sevasemten missed its Phase III GRAND CANYON primary endpoint in Becker muscular dystrophy. Read how these results ...

Camurus has dosed the first patient in LUNAR-2, a Phase IIb study of monthly semaglutide depot CAM2056 for obesity. Explore ...

Moderna (Nasdaq: MRNA) has dosed the first participants in the first clinical trial of a vaccine specifically targeting Bundibugyo ebolavirus (BDBV). The mRNA candidate enters development as the ...

Columbia researchers show deleting certain sugar transport genes helps E. coli colonize tumors better. Learn how this could ...